For how we live.
From 300 million laboratory tests, an Israeli team reconstructs trajectories and finds bone, liver, kidney, hormone and lipid markers shift abruptly at the final menstrual period — changes starting a decade earlier.
A meta-analysis of 36 studies and 2.6 million women found iatrogenic menopause raised stroke and cardiovascular risk. The death-rate excess was confined to menopause before 45, with null estimates after.
Eli Lilly's oral Inluriyo gained an FDA efficacy supplement on 18 September. In the phase 3 EMBER-3 trial, adding abemaciclib lifted median progression-free survival to 9.4 months from 5.5.
Emcitate cleared the FDA on 28 September as a new molecular entity. In an open-label trial of 45 patients, the drug lowered the high serum T3 that drives MCT8 deficiency by about two-thirds.
Products promising to 'balance your hormones' lean on botanicals like maca, black cohosh and phytoestrogens, and on the hormone DHEA. When those ingredients are put in controlled trials, the evidence is limited or null.
Cognitive behavioural therapy is one of the few non-hormone options the North American Menopause Society backs at its top evidence level. What it changes is how much flushes bother you, not the thermostat.
Testosterone raises desire mostly in men whose levels are genuinely low, and the effect is modest. In the largest trial, the size of the hormone rise, not a threshold, tracked with benefit.
Sold as natural, safer and tailored by hormone testing, custom-compounded menopausal hormones are untested against approved options — and expert panels advise restricting their use.
Exogenous testosterone switches off the body's own signals to the testes. In a male-contraceptive trial, 95.9 per 100 men fell to near-zero sperm counts. The effect is usually, but not always, reversible.
Men are under 1% of breast-cancer cases, but they present older and at higher stage, and survival has improved more slowly than in women. Care is largely borrowed from female breast cancer.
Enlarged male breast gland tissue is common and usually benign. In a study of 19,640 young males, about three-quarters of cases were idiopathic and only 3.4% were linked to underlying disease.
In LIBERTY 1 and 2, more than 70% of women with fibroid-related heavy bleeding responded to the once-daily pill, versus under 20% on placebo. The label caps use at 24 months over bone loss.
A secondary analysis of the ELITE hormone-therapy trial found hints that social ties tracked with cognition, but none survived correction for multiple testing.
SERENA-6 changed therapy the moment a resistance mutation appeared in the blood, not when tumours grew. It nearly doubled time to progression — and won camizestrant FDA approval in 2026.
In a 92-patient Greek cohort, the long-acting PTH replacement normalised calcium and phosphate and freed 58% of patients from calcium and vitamin D pills — echoing the trials, over a short follow-up.
Young men are chasing higher testosterone with 'natural boosters' and direct-to-consumer TRT. The supplements are largely unproven; unnecessary therapy carries real costs to fertility.
Six products got revised labels in February 2026, removing cardiovascular, breast cancer, and dementia language. The scientific societies that welcomed the change also listed the distinctions the new label does not make.
A Finnish registry of over 123,000 women found pre-eclampsia linked to an 11% lower breast cancer risk decades later. Hormone therapy raised risk by a similar amount in both groups.
A 150-woman real-world comparison found combination therapy cut symptom scores further and produced more clinical responders. Endometrial thickness rose slightly but stayed normal.
A Finnish national registry of over 11,000 women found up to 94% of endometriosis patients used menopausal hormone therapy after surgery, against 82% of a comparison group. The mix of hormones used is changing too.
In the phase 3 PATCH trial, oestrogen skin patches were non-inferior to LHRH injections for three-year metastasis-free survival, with fewer hot flushes but more breast swelling.
Pooling decades of research, the combined estrogen-progestin regimen showed a 44% higher breast cancer risk. Estrogen-only therapy showed none in observational studies — and trials suggested it lowered risk.
A Taiwanese cohort of 26,000 women aged 20 to 50 puts numbers on a known tamoxifen risk in a population — younger, premenopausal — where data has been thinner.
A nationwide register study found a hazard ratio of 0.96 for all-cause death among users of menopausal hormone therapy. The raw death rate in users was higher — which is the part worth understanding.
The consensus statement does not claim the treatment is safe after breast cancer. It says some women may reasonably accept an increased relapse risk in exchange for symptom relief.
Pooling ten studies, researchers found menopause hormone therapy neither raised nor lowered dementia risk. The certainty of that evidence ranged from moderate to very low.
A UK-wide survey found cognitive and psychological symptoms outranked the ones menopause care is organised around, with higher ratings among Asian and Black respondents.
An EMAS clinical guide sets out how to manage endometriosis after menopause, advising against oestrogen-only hormone therapy even in women who have had a hysterectomy.